Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 2015

View Archived Issues

Long-term data for olokizumab in rheumatoid arthritis

Tolerability of pevonedistat with docetaxel, paclitaxel/carboplatin or gemcitabine

Otsuka Pharmaceutical reviews highlights of third quarter 2015

Antibe licenses Knight Therapeutics rights for pain and inflammation drugs

MGB Biopharma completes feasibility study of topical MGB-BP-3

Cinfa Biotech treats first subjects with biosimilar pegfilgrastim

ProMetic reveals agent under development for diabetic nephropathy

First-in-patient data for anti-fractalkine MAb E-6011 in RA

Phase I results for FPA-008 in RA

Pfizer discloses antineoplastic compounds

Roche patents TAAR1 ligands

Medshine Discovery presents ROCK inhibitors

Shanghai Institute Materia Medica divulges KCNQ2 activators

Jiangsu Kanion Pharmaceutical and Medshine Discovery report anti-EV71 compounds

Genoscience's first-in-class autophagy inhibitor GNS-561

Tragara and Lee's Pharma to develop TG-02 in China and South East Asia

Genentech opts-in to the Ophthotech/Novartis ex-U.S. agreement for Fovista

European Commission approves expanded uses of Kalydeco for cystic fibrosis

Turing initiates phase I trial of TUR-004 for epileptic encephalopathies

Gemphire Therapeutics presents preclinical and clinical data for gemcabene

Phase II results with hepcortespenlisimut-L in HCC lead to phase III trial

Vigilant Biosciences receives CE mark for OncAlert oral cancer CD44/total protein lab test

MRG-106 enters phase I trial in patients with CTCL

Depomed licenses rights to Gruenenthal's analgesic cebranopadol

Actinium files IND for phase III trial of Iomab-B

Summit Therapeutics and University of Oxford extend utrophin collaboration

FDA grants orphan drug designation to Amyndas Pharmaceuticals' Compstatin 40

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...